Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $10,110,417.12 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 16,083 shares of the stock in a transaction that occurred on Wednesday, September 23rd. The stock was sold at an average price of $628.64, for a total transaction of $10,110,417.12. Following the transaction, the chief executive officer directly owned 417,289 shares in the company, valued at approximately $262,324,556.96. This represents a 3.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Medpace Price Performance

MEDP stock traded down $1.71 during trading on Friday, reaching $618.88. 229,012 shares of the stock traded hands, compared to its average volume of 332,429. The firm has a market capitalization of $17.27 billion, a PE ratio of 36.28, a P/E/G ratio of 2.81 and a beta of 1.15. The business’s 50 day moving average price is $593.03 and its 200-day moving average price is $515.26. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MEDP. Royal Bank Of Canada lifted their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Truist Financial increased their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Medpace in a report on Monday, September 14th. Finally, Barclays set a $600.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medpace has a consensus rating of “Hold” and an average price target of $595.20.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. American Capital Management Inc. bought a new position in Medpace in the 2nd quarter valued at $111,329,000. Focus Partners Advisor Solutions LLC acquired a new stake in shares of Medpace during the 2nd quarter worth approximately $1,685,000. California State Teachers Retirement System raised its stake in shares of Medpace by 22.1% during the first quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock worth $12,505,000 after buying an additional 4,719 shares during the last quarter. BlackRock Inc. bought a new position in Medpace in the second quarter valued at approximately $1,323,047,000. Finally, Madison Asset Management LLC acquired a new position in shares of Medpace in the 2nd quarter valued at $128,956,000. 77.98% of the stock is owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.